Please use this identifier to cite or link to this item:
https://www.arca.fiocruz.br/handle/icict/37904
Type
ArticleCopyright
Open access
Collections
- INI - Artigos de Periódicos [3646]
Metadata
Show full item record37
CITATIONS
37
Total citations
22
Recent citations
6.4
Field Citation Ratio
2.69
Relative Citation Ratio
THE POPULATION IMPACT OF LATE PRESENTATION WITH ADVANCED HIV DISEASE AND DELAYED ANTIRETROVIRAL THERAPY IN ADULTS RECEIVING HIV CARE IN LATIN AMERICA
Author
Belaunzarán-Zamudio, Pablo F.
Caro-Vega, Yanink N.
Shepherd, Bryan E.
Rebeiro, Peter F.
Crabtree-Ramírez, Brenda E.
Cortes, Claudia P.
Grinsztejn, Beatriz
Gotuzzo, Eduardo
Mejia, Fernando
Padgett, Denis
Pape, Jean W.
Rouzier, Vanessa
Veloso, Valdiléa G.
Cardoso, Sandra Wagner
McGowan, Catherine C.
Sierra-Madero, Juan G.
Caro-Vega, Yanink N.
Shepherd, Bryan E.
Rebeiro, Peter F.
Crabtree-Ramírez, Brenda E.
Cortes, Claudia P.
Grinsztejn, Beatriz
Gotuzzo, Eduardo
Mejia, Fernando
Padgett, Denis
Pape, Jean W.
Rouzier, Vanessa
Veloso, Valdiléa G.
Cardoso, Sandra Wagner
McGowan, Catherine C.
Sierra-Madero, Juan G.
Affilliation
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán. Departamento de Infectología. Mexico City, Mexico.
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán. Departamento de Infectología. Mexico City, Mexico.
Vanderbilt University. Department of Biostatistics. Nashville, TN, USA.
Vanderbilt University. Department of Medicine. Nashville, TN, USA.
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán. Departamento de Infectología. Mexico City, Mexico.
Universidad de Chile. Fundación Arriarán. Santiago, Chile.
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Laboratório de Pesquisa Clínica em DST/AIDS. Rio de Janeiro, RJ, Brasil.
Instituto de Medicina Tropical Alexander von Humboldt. Lima, Peru.
Instituto de Medicina Tropical Alexander von Humboldt. Lima, Peru.
Instituto Hondureño de Seguridad Social. Tegucigalpa, Honduras / Hospital Escuela. Tegucigalpa, Honduras.
Le Groupe Haitien d’Etude du Sarcome de Kaposi et des Infections Opportunistes. Port-au-Prince, Haiti.
Le Groupe Haitien d’Etude du Sarcome de Kaposi et des Infections Opportunistes. Port-au-Prince, Haiti.
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Laboratório de Pesquisa Clínica em DST/AIDS. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Laboratório de Pesquisa Clínica em DST/AIDS. Rio de Janeiro, RJ, Brasil.
Vanderbilt University. Department of Medicine. Nashville, TN, USA.
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán. Departamento de Infectología. Mexico City, Mexico.
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán. Departamento de Infectología. Mexico City, Mexico.
Vanderbilt University. Department of Biostatistics. Nashville, TN, USA.
Vanderbilt University. Department of Medicine. Nashville, TN, USA.
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán. Departamento de Infectología. Mexico City, Mexico.
Universidad de Chile. Fundación Arriarán. Santiago, Chile.
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Laboratório de Pesquisa Clínica em DST/AIDS. Rio de Janeiro, RJ, Brasil.
Instituto de Medicina Tropical Alexander von Humboldt. Lima, Peru.
Instituto de Medicina Tropical Alexander von Humboldt. Lima, Peru.
Instituto Hondureño de Seguridad Social. Tegucigalpa, Honduras / Hospital Escuela. Tegucigalpa, Honduras.
Le Groupe Haitien d’Etude du Sarcome de Kaposi et des Infections Opportunistes. Port-au-Prince, Haiti.
Le Groupe Haitien d’Etude du Sarcome de Kaposi et des Infections Opportunistes. Port-au-Prince, Haiti.
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Laboratório de Pesquisa Clínica em DST/AIDS. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Laboratório de Pesquisa Clínica em DST/AIDS. Rio de Janeiro, RJ, Brasil.
Vanderbilt University. Department of Medicine. Nashville, TN, USA.
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán. Departamento de Infectología. Mexico City, Mexico.
Abstract
Late presentation to care and antiretroviral therapy (ART) initiation with advanced HIV-disease are common in Latin America. We estimated the impact of these conditions on mortality in the region. We included adults enrolled during 2001-2014 at HIV-care clinics. We estimated the adjusted attributable risk (AR) and population attributable fraction (PAF) for all-cause mortality of presentation to care with advanced HIV-disease (advanced-LP), ART initiation with advanced HIV-disease, and not initiating ART. Advanced HIV-disease was defined as CD4<200 cells/μL or AIDS. AR and PAF were derived using marginal structural models. Of 9,229 patients, 56% presented with advanced HIV-disease. ARs of death for advanced-LP were 86%, 71%, and 58%, and PAFs were 78%, 58%, and 43% at 1, 5, and 10 years post-enrollment. Among people without advanced-LP, ARs of death for delaying ART were 39%, 32%, and 37% at 1, 5, and 10 years post-enrollment and PAFs were 20%, 14%, and 15%. Among people with advanced-LP, ART decreased the hazard of death by 63% in the first year post-enrollment, but 93% of these started ART; thus universal ART among them would only reduce mortality by 10%. Earlier presentation to care and earlier ART initiation would prevent most HIV-deaths in Latin America.
Share